Proceedings of the third global workshop on chronic myeloid leukemia

Giuseppe Saglio, Hagop Kantarjian, Tessa Holyoake, Aarati Ranganathan, Jorge E. Cortés

Research output: Contribution to journalArticle

Abstract

Tyrosine kinase inhibitor (TKI) therapy has resulted in unprecedented responses and survival rates in Philadelphia chromosome positive chronic myelogenous leukemia (CML) that are durable for years. However, a third of patients either fail to respond or respond suboptimally to imatinib therapy, while some others are intolerant to imatinib. Increased understanding of the molecular basis of imatinib resistance has led to rational development of second-generation TKIs as effective second-line treatment options for imatinib-resistant patients. However, persistence of minimal residual disease (MRD) and development of resistance against TKI therapy are proving to be significant challenges. Treatment options are evolving for patients with CML and the promising results with several novel agents showing activity in CML, including in patients with the T315I mutation, are encouraging advancements in the field. Recently, a panel of global experts in CML deliberated on the imminent approval of second-generation TKIs in the frontline setting, ways to improve on frontline therapy, integration of new agents in current treatment algorithms, and design of future clinical trials; the proceedings of the discussion are summarized in this article.

Original languageEnglish (US)
Pages (from-to)443-451
Number of pages9
JournalClinical Lymphoma, Myeloma and Leukemia
Volume10
Issue number6
DOIs
StatePublished - Dec 2010
Externally publishedYes

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Education
Protein-Tyrosine Kinases
Therapeutics
Philadelphia Chromosome
Disease Resistance
Residual Neoplasm
Survival Rate
Clinical Trials
Mutation
Imatinib Mesylate

Keywords

  • Bcr-abl
  • Chronic myelogenous leukemia
  • Dasatinib
  • Imatinib
  • T315I mutation
  • Tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Proceedings of the third global workshop on chronic myeloid leukemia. / Saglio, Giuseppe; Kantarjian, Hagop; Holyoake, Tessa; Ranganathan, Aarati; Cortés, Jorge E.

In: Clinical Lymphoma, Myeloma and Leukemia, Vol. 10, No. 6, 12.2010, p. 443-451.

Research output: Contribution to journalArticle

Saglio, Giuseppe ; Kantarjian, Hagop ; Holyoake, Tessa ; Ranganathan, Aarati ; Cortés, Jorge E. / Proceedings of the third global workshop on chronic myeloid leukemia. In: Clinical Lymphoma, Myeloma and Leukemia. 2010 ; Vol. 10, No. 6. pp. 443-451.
@article{28837c82b34847a2bc7268367a666cda,
title = "Proceedings of the third global workshop on chronic myeloid leukemia",
abstract = "Tyrosine kinase inhibitor (TKI) therapy has resulted in unprecedented responses and survival rates in Philadelphia chromosome positive chronic myelogenous leukemia (CML) that are durable for years. However, a third of patients either fail to respond or respond suboptimally to imatinib therapy, while some others are intolerant to imatinib. Increased understanding of the molecular basis of imatinib resistance has led to rational development of second-generation TKIs as effective second-line treatment options for imatinib-resistant patients. However, persistence of minimal residual disease (MRD) and development of resistance against TKI therapy are proving to be significant challenges. Treatment options are evolving for patients with CML and the promising results with several novel agents showing activity in CML, including in patients with the T315I mutation, are encouraging advancements in the field. Recently, a panel of global experts in CML deliberated on the imminent approval of second-generation TKIs in the frontline setting, ways to improve on frontline therapy, integration of new agents in current treatment algorithms, and design of future clinical trials; the proceedings of the discussion are summarized in this article.",
keywords = "Bcr-abl, Chronic myelogenous leukemia, Dasatinib, Imatinib, T315I mutation, Tyrosine kinase inhibitors",
author = "Giuseppe Saglio and Hagop Kantarjian and Tessa Holyoake and Aarati Ranganathan and Cort{\'e}s, {Jorge E.}",
year = "2010",
month = "12",
doi = "10.3816/CLML.2010.n.077",
language = "English (US)",
volume = "10",
pages = "443--451",
journal = "Clinical Lymphoma, Myeloma and Leukemia",
issn = "2152-2650",
publisher = "Cancer Media Group",
number = "6",

}

TY - JOUR

T1 - Proceedings of the third global workshop on chronic myeloid leukemia

AU - Saglio, Giuseppe

AU - Kantarjian, Hagop

AU - Holyoake, Tessa

AU - Ranganathan, Aarati

AU - Cortés, Jorge E.

PY - 2010/12

Y1 - 2010/12

N2 - Tyrosine kinase inhibitor (TKI) therapy has resulted in unprecedented responses and survival rates in Philadelphia chromosome positive chronic myelogenous leukemia (CML) that are durable for years. However, a third of patients either fail to respond or respond suboptimally to imatinib therapy, while some others are intolerant to imatinib. Increased understanding of the molecular basis of imatinib resistance has led to rational development of second-generation TKIs as effective second-line treatment options for imatinib-resistant patients. However, persistence of minimal residual disease (MRD) and development of resistance against TKI therapy are proving to be significant challenges. Treatment options are evolving for patients with CML and the promising results with several novel agents showing activity in CML, including in patients with the T315I mutation, are encouraging advancements in the field. Recently, a panel of global experts in CML deliberated on the imminent approval of second-generation TKIs in the frontline setting, ways to improve on frontline therapy, integration of new agents in current treatment algorithms, and design of future clinical trials; the proceedings of the discussion are summarized in this article.

AB - Tyrosine kinase inhibitor (TKI) therapy has resulted in unprecedented responses and survival rates in Philadelphia chromosome positive chronic myelogenous leukemia (CML) that are durable for years. However, a third of patients either fail to respond or respond suboptimally to imatinib therapy, while some others are intolerant to imatinib. Increased understanding of the molecular basis of imatinib resistance has led to rational development of second-generation TKIs as effective second-line treatment options for imatinib-resistant patients. However, persistence of minimal residual disease (MRD) and development of resistance against TKI therapy are proving to be significant challenges. Treatment options are evolving for patients with CML and the promising results with several novel agents showing activity in CML, including in patients with the T315I mutation, are encouraging advancements in the field. Recently, a panel of global experts in CML deliberated on the imminent approval of second-generation TKIs in the frontline setting, ways to improve on frontline therapy, integration of new agents in current treatment algorithms, and design of future clinical trials; the proceedings of the discussion are summarized in this article.

KW - Bcr-abl

KW - Chronic myelogenous leukemia

KW - Dasatinib

KW - Imatinib

KW - T315I mutation

KW - Tyrosine kinase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=79952961509&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952961509&partnerID=8YFLogxK

U2 - 10.3816/CLML.2010.n.077

DO - 10.3816/CLML.2010.n.077

M3 - Article

C2 - 21156461

AN - SCOPUS:79952961509

VL - 10

SP - 443

EP - 451

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

SN - 2152-2650

IS - 6

ER -